Saksoft has approved the appointment of Gurmeet Chahal as Chief Executive Officer of Saksoft Inc, its material US subsidiary, effective October 12, 2026. The board also designated him as Senior Management Personnel of the parent company with effect from his joining date.

Leadership appointment at Saksoft Inc

The company's board approved the appointment of Gurmeet Chahal to lead Saksoft Inc as its CEO. The role takes effect on October 12, 2026. This decision follows the recommendation of the Nomination and Remuneration Committee. In addition to leading the US entity, Mr. Chahal will be designated as Senior Management Personnel of Saksoft Limited, enhancing governance visibility for the subsidiary's operations.

Executive profile and experience

Mr. Chahal is a senior technology and business-services executive with approximately three decades of experience across IT services, BPM, digital transformation, healthcare, and life sciences. He has worked extensively across India and the US and is currently based in New Jersey.

His recent roles include serving as the Founding Chief Executive Officer and Executive Director of Digitide, where he led the transformation of the business following its demerger from Quess Corp. Prior to Digitide, he was Senior Vice President & Global Leader – Digital Transformation Services at Genpact from 2021 to 2024. At Genpact, he was responsible for repositioning the digital transformation business and driving growth through integrated technology/BPM offerings, partnerships, and new-logo acquisition.

Mr. Chahal holds a Bachelor of Technology in Chemical Engineering from Panjab University and an MBA in Finance & Marketing from XLRI, Jamshedpur. He has also completed executive programmes at Northwestern Kellogg and Tuck School of Business, Dartmouth. He is not related to any director of the company.

Saksoft Limited has received sanction from the National Company Law Tribunal (NCLT), Chennai Bench, for the amalgamation of its wholly owned subsidiary, Augmento Labs Private Limited, with and into the company. The order was pronounced on September 16, 2026, marking a significant step in the company's corporate restructuring efforts.

The NCLT approved the Scheme of Amalgamation under Sections 230 to 232 of the Companies Act, 2013. The Appointed Date for the merger is set as April 1, 2026. The scheme will become effective upon the filing of the certified copy of the order with the Registrar of Companies, Chennai.

Strategic Rationale and Benefits

The primary objective of the amalgamation is to consolidate entities within the Saksoft group, thereby simplifying the holding structure by eliminating multiple legal entities. According to the scheme details, this move is expected to drive greater efficiency in the combined business through economies of scale and operational rationalization.

Key benefits highlighted in the filing include:

• Elimination of inter-corporate dependencies and duplication of activities.
• Reduction in administrative, managerial, and overhead costs.
• Minimization of multiplicity of legal and regulatory compliances.
• Enhanced cash flow management and unfettered access to funds for growth opportunities.

Accounting Treatment and Compliance

The transaction will be accounted for using the Pooling of Interest Method as prescribed in Ind AS 103 (Appendix C) for business combinations under common control. Upon the scheme becoming effective, all assets, liabilities, and reserves of Augmento Labs will vest in Saksoft. The shares of the transferor company held by Saksoft will stand cancelled without any further act or deed.

The NCLT noted that while the Regional Director raised certain observations regarding employee protection and appointed date clarity, the petitioners provided necessary undertakings. These include commitments not to alter the Appointed Date without tribunal approval and to ensure no retrenchment of employees in service as of the Appointed Date.

What the Numbers Show

A critical observation from the regulatory filings reveals that the acquisition consideration for Augmento Labs was determined on an arm's-length basis under a Share Purchase Agreement dated June 12, 2024. The total purchase price comprised an upfront payment of ₹35 crore and deferred earnout payments linked to financial performance parameters. The petitioners clarified that the entire consideration, including deferred amounts totaling ₹97.5 crore, has been paid in full. This confirms that the acquisition was complete prior to the merger sanction, ensuring that the amalgamation proceeds without additional cash outflow obligations for the transferee company.